Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO) is a publicly traded Healthcare sector company. As of May 21, 2026, OBIO trades at $3.98 with a market cap of $238.33M and a P/E ratio of -3.57. OBIO moved +0.13% today. Year to date, OBIO is -6.13%; over the trailing twelve months it is +34.92%. Its 52-week range spans $2.20 to $6.50. Analyst consensus is strong buy with an average price target of $13.40. Rallies surfaces OBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Orchestra BioMed Raises $35M, Targets BACKBEAT Enrollment by Q3 2026: Orchestra BioMed ended Q1 2026 with $94.4 million in cash and received $35 million strategic capital from Medtronic and Ligand, supporting projected cash runway into Q4 2027. The company targets BACKBEAT Trial enrollment completion by end of Q3 2026 and secured FDA Breakthrough Device Designation for AVIM Therapy.
| Metric | Value |
|---|---|
| Price | $3.98 |
| Market Cap | $238.33M |
| P/E Ratio | -3.57 |
| EPS | $-1.11 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.50 |
| 52-Week Low | $2.20 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $33.48M |
| Net Income | $-52.70M |
| Gross Margin | 99.43% |
6 analysts cover OBIO: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.40.